MedDataX Logo

Study to Evaluate the Effect of Aficamten Administration on QT/QTc Interval

NCT ID: NCT05924815

Last Updated: 2023-12-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

44 participants

Study Classification

INTERVENTIONAL

Study Start Date

2023-05-15

Study Completion Date

2023-11-14

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a single-center, 2-part (Part A and Part B) study in healthy participants. Part A (Dose Finding) is an open-label, SAD study to identify the dose for Part B. Part B (TQT Study) is a randomized, double-blind (with respect to aficamten and matching placebo), positive- and placebo-controlled, single-dose, 3-way crossover study to evaluate the effect of aficamten administration on QT/QTc interval.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Participants

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

CK-3773274 CK-274 Aficamten

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Part A (Dose Finding Cohort 1): Aficamten 50 mg

Participants in this arm will receive a single oral dose of 50 mg aficamten.

Group Type EXPERIMENTAL

Aficamten

Intervention Type DRUG

Oral Tablet

Part A (Dose Finding Cohort 2): Aficamten 75 mg

Participants in this arm will receive a single oral dose up to 75 mg aficamten.

Group Type EXPERIMENTAL

Aficamten

Intervention Type DRUG

Oral Tablet

Part A (Dose Finding Cohort 3): Aficamten 100 mg

Participants in this arm will receive a single oral dose up to 100 mg aficamten.

Group Type EXPERIMENTAL

Aficamten

Intervention Type DRUG

Oral Tablet

Part B (TQT Study): Aficamten

Participants will receive a single oral dose of aficamten. The dose will be determined based on review of Part A PK parameters, echocardiogram parameters, safety, and tolerability for aficamten.

Group Type EXPERIMENTAL

Aficamten

Intervention Type DRUG

Oral Tablet

Part B (TQT Study): Aficamten-matching Placebo

Participants in this arm will receive a single oral dose of aficamten-matching placebo.

Group Type PLACEBO_COMPARATOR

Aficamten-matching Placebo

Intervention Type DRUG

Oral Tablet

Part B (TQT Study): Moxifloxacin 400 mg

Participants will receive a single oral dose of 400 mg moxifloxacin

Group Type ACTIVE_COMPARATOR

Moxifloxacin

Intervention Type DRUG

Oral Tablet

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Aficamten

Oral Tablet

Intervention Type DRUG

Aficamten-matching Placebo

Oral Tablet

Intervention Type DRUG

Moxifloxacin

Oral Tablet

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy, adult, male or female, 18-45 years of age, inclusive, at the screening visit.
* Continuous non-smoker who has not used nicotine- and tobacco -containing products for at least 3 months prior to the first dosing based on participant self- reporting.
* Body mass index (BMI) ≥ 18.0 and ≤ 30.0 kg/m2 at the screening visit.
* Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, and vital signs, as deemed by the PI or designee, including the following:

* Supine blood pressure is ≥ 90/40 mmHg and ≤ 140/90 mmHg at the screening visit.
* Oxygen saturation (SpO2) is ≥ 95% at the screening visit.
* Liver function tests (e.g., bilirubin, aspartate aminotransferase \[AST\], alanine aminotransferase \[ALT\]) considered not clinically significant in the opinion of the PI or designee at the screening visit.
* Estimated creatinine clearance ≥ 90 mL/min at the screening visit.
* No clinically significant history and presence of ECG findings as judged by the PI or designee at the screening visit and first check-in, including each of the following:

* HR between 50 bpm and 100 bpm, inclusive.
* QTcF interval is ≤450 msec (males) and ≤460 msec (females).
* QRS ≤110 msec; if \>110 msec, result will be confirmed by a manual over read.
* PR ≤220 msec.
* LVEF ≥65% at the screening visit.

Exclusion Criteria

* History of any illness that, in the opinion of the PI or designee, might confound the results of the study or poses an additional risk to the participant by their participation in the study.
* History or presence of alcohol or drug abuse within the past 2 years prior to the first dosing.
Minimum Eligible Age

18 Years

Maximum Eligible Age

45 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Cytokinetics

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Cytokinetics, MD

Role: STUDY_DIRECTOR

Cytokinetics

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Celerion, Inc 2420

Tempe, Arizona, United States

Site Status

Countries

Review the countries where the study has at least one active or historical site.

United States

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CY 6019

Identifier Type: -

Identifier Source: org_study_id